ArticleApplied biochemistry and biotechnology2026
CEBPD-MMP8 Axis Contributes to Cardiomyocyte Injury in Septic Shock.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Sepsis-associated myocardial injury is a life-threatening condition, yet its underlying molecular mechanisms remain poorly understood. This study investigates the pathophysiological roles of the stress-responsive transcription factor CCAAT/enhancer-binding protein delta (CEBPD) and matrix metalloproteinase-8 (MMP8), hypothesizing that they constitute a key signaling axis in septic cardiomyopathy. An in vitro sepsis model was established using primary neonatal rat cardiomyocytes (NRCMs), which were exposed to serum derived from validated animal models of sepsis/septic shock and corresponding controls to mimic the clinical microenvironment. Gene expression, cell viability, apoptosis, and inflammatory responses were assessed using a range of molecular and cellular biology approaches. Direct regulatory interactions were verified through dual-luciferase reporter and chromatin immunoprecipitation assays, while functional relevance was further confirmed via rescue experiments. CEBPD expression was significantly elevated in the serum of endotoxin shock animals as well as in serum-stimulated NRCMs. Moreover, CEBPD overexpression promoted cardiomyocyte apoptosis and inflammation, whereas its silencing conferred protection by attenuating cellular injury and inflammatory activity. Mechanistically, CEBPD was shown to directly transactivate MMP8. Notably, MMP8 knockdown reproduced the protective effects against apoptosis observed following CEBPD suppression. Conversely, enforced MMP8 expression completely reversed the anti-apoptotic and anti-inflammatory effects of CEBPD knockdown, identifying MMP8 as a critical downstream mediator of CEBPD-driven pathogenicity. These findings delineate a potential mechanism underlying septic cardiomyopathy mediated through the CEBPD–MMP8 signaling pathway. Septic stress induces CEBPD upregulation, which directly activates MMP8 expression, thereby triggering cardiomyocyte apoptosis and inflammation. This newly characterized axis highlights a mechanistically informed target for future therapeutic exploration in septic cardiomyopathy.
Indexed as
Identifiers
42018133What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.